Vertex (VRTX) Orkambi Briefing Docs 'Positive Overall', Baird Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls over 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
UPDATE: Vertex Pharma's (VRTX) Orkamibi Recommended for Approval by FDA Panel
May 12, 2015 3:42 PM EDT(Updated - May 12, 2015 3:46 PM EDT)
Vertex Pharma (NASDAQ: VRTX) Orkamibi Recommended for Approval by FDA Panel. According to Bloomberg, the panel vote was 12-1.
Previously, the FDA panel said Orkambi is safe to treat cystic fibrosis and that it couldn't determine if Lumacaftor contributes positively to Orkambi combo.
... MoreVertex Pharma (VRTX) Shares Halted Ahead of FDA Advisory Committee Meeting
May 12, 2015 7:31 AM EDTVertex Pharma (NASDAQ: VRTX) shares were halted for news ahead of an FDA advisory committee meeting on Orkambi.
... MoreRBC Comments on Vertex (VRTX) Following Orkambi Briefing Docs
May 8, 2015 10:03 AM EDTRBC Capital maintained an Outperform rating on Vertex (NASDAQ: VRTX) with a price target of $130. Shares weakened after the FDA posted Orkambi briefing docs, although they have since recovered. Analyst Michael J. Yee called the decline a buying opportunity.
Yee explained, "At first glance topics appear obvious: 1) asking on the magnitude of benefit; and 2) and comment on efficacy... More
Vertex Pharma (VRTX) on Watch After FDA Posts Briefing Docs for Orkambi to Treat CF
May 8, 2015 8:03 AM EDTThe FDA posted briefing docs related to Vertex Pharma's (NASDAQ: VRTX) lumacaftor/ivacaftor (Orkambi) combination oral tablets for the treatment of cystic fibrosis.
... More